Published Studies Related to Prostin VR Pediatric (Alprostadil)
Well-designed clinical trials related to Prostin VR Pediatric (Alprostadil)
Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. [2007.10]
Effects of pentoxifylline and alprostadil on ocular hemodynamics in healthy humans. [2007.02]
[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)] [2007]
An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. [2006.08]
Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy. [2006.03]
[Reevaluation of protective effects of alprostadil on hepatic function in patients undergoing hepatectomy] [2005.09]
Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. [2005.01]
Well-designed clinical trials possibly related to Prostin VR Pediatric (Alprostadil)
Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. [2008.06]
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. [2008.04]
Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). [2008.01]
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. [2008.01]
Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. [2007.10]
Efficacy and safety of misoprostol in induction of labour in a Nigerian tertiary hospital. [2007.07]
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. [2007.06.01]
Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. [2007.05]
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. [2007.02]
Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. [2006.12]
Intraamniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy. [2006.06.01]
The effects of prostaglandin E-1 in patients with intermittent claudication. [2006.06]
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. [2006.05]
Prostaglandin E1 attenuates impairment of cellular immunity after cardiopulmonary bypass. [2006.04]
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. [2006.04]
Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. [2006.03.01]
Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. [2006.03]
An investigation of misoprostol in the promotion of wound healing. [2006]
Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. [2005.12]
Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. [2005.12]
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. [2005.12]
Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. [2005.08]
Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. [2005.08]
Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss. [2005.07]
Priming effect of misoprostol on estrogen pretreated cervix in postmenopausal women. [2005.07]
A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. [2005.07]
Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. [2005.06]
Effect of glutamine on water and sodium absorption in human jejunum at baseline and during PGE1-induced secretion. [2005.06]
Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1. [2005.05]
Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy. [2005.03]
Second trimester abortion using isosorbide mononitrate in addition to gemeprost compared with gemeprost alone: a double-blind randomized, placebo-controlled multicenter trial. [2005.03]
Medical versus surgical abortion: comparing satisfaction and potential confounders in a partly randomized study. [2005.03]
Saturation with oxygen for ductal dependent congenital heart diseases before and after the prostaglandin therapy. [2005.02]
Other research related to Prostin VR Pediatric (Alprostadil)
Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study in chinese population. [2008.08]
Efficacy and Safety of Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder: A Double-Blind, Placebo-Controlled Study in Chinese Population. [2008.06.18]
An overview and expert opinion on the use of alprostadil in the treatment of sexual dysfunction. [2008.06]
[Effects of alprostadil in prevention of portal vein thrombogenesis after splenectomy and devascularization: a clinical observation of 76 patients with portal hypertension] [2008.02.26]
The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. [2007.12]
Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion: the effect of alprostadil. [2006.12]
Rapid improvement of distal vasculitis in PAN related to hepatitis B with alprostadil infusion: a case report. [2006.08]
Topical alprostadil treatment of female sexual arousal disorder. [2006.07]
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). [2005.09]
Other possibly related research studies
Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment. [2006.12]
Limaprost. [2007]
Successful liver transplantation across the ABO incompatibility barrier in 6 cases of biliary atresia. [2006.12]
Water-soluble HPMA copolymer--prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. [2006.07]
DDS for anti-aging and regenerative medicine (review). [2006]
Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant. [2006.11]
Misoprostol (alone) in second trimester terminations of pregnancy: as effective as Gemeprost? [2006.08]
Prostaglandin E(2) protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP(2) receptor activation. [2007.01]
Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. [2006.09]
Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats. [2006.09]
Systemic levels following PGE1 inhalation in neonatal hypoxemic respiratory failure. [2006.09]
Pneumatosis cystoides intestinalis with systemic sclerosis, limited type resulting in a poor prognosis. [2006.08]
Cardiopulmonary effects of intravenous prostaglandin E1 during experimental one-lung ventilation. [2006.08]
Pathophysiology and treatment of diabetic erectile dysfunction. [2006.11]
[The effect of prostaglandin E1 infusion on circulating system in patients undergoing surgical procedure because of abdominal aortic aneurysm] [2006.05]
Chronic constipation: let symptom type and severity direct treatment. [2006.07]
Treatment of erectile dysfunction in multiple sclerosis. [2006.06]
[Acute ischemia of the hand after intra-arterial injection of flunitrazepam. Local combined fibrinolysis therapy in three cases] [2006.06.16]
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. [2006.06]
The use of prostaglandins in the immediate postsurgical liver transplant period. [2006.05]
[Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible] [2006.05]
Bile acids stimulate PKCalpha autophosphorylation and activation: role in the attenuation of prostaglandin E1-induced cAMP production in human dermal fibroblasts. [2006.08]
Lubiprostone. [2006]
Measurement of induced acrosome reactions in human sperm using physiologic stimuli--relevance for the prediction of fertilization outcome. [2006.06]
Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. [2006.04.15]
Response of cochlear blood flow to prostaglandin E1 applied topically to the round window. [2006.03]
Influence of groin incision, duration of ischemia, and prostaglandin E1 on ischemia-reperfusion injury of the lower limb. [2006.04]
Cutaneous polyarteritis nodosa presented with digital gangrene: a case report. [2006.04]
Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease. [2006.05]
Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. [2006]
Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. [2006.04]
Evaluation and medical management of erectile dysfunction. [2006.03]
n-6 and n-3 polyunsaturated fatty acids down-regulate cytochrome P-450 2B1 gene expression induced by phenobarbital in primary rat hepatocytes. [2006.10]
Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy. [2006]
Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. [2006.03]
Early treatment of cavernositis resulted in erectile function preservation. [2006.03]
Effect of gamma-linolenic acid and prostaglandins E1 on gamma-radiation and chemical-induced genetic damage to the bone marrow cells of mice. [2006.03]
Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. [2006.09]
Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis. [2006.01]
Late-stage clinical development in lower urogenital targets: sexual dysfunction. [2006.02]
Effect of prostaglandin E1 on ischemia-reperfusion injury during abdominal aortic aneurysm surgery. [2006]
Basic fibroblast growth factor treatment for skin ulcerations in scleroderma. [2005.12]
Use of a visual analog scale to assess pain of injection with intracavernous injection therapy. [2005.05]
1-hydroxyPGE reduces infarction volume in mouse transient cerebral ischemia. [2006.01]
Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure. [2005.09]
Intracavernous injection of prostaglandin E1 is effective in patients with erectile dysfunction not responding to phosphodiseterase 5 inhibitors. [2005.12]
Current pathological and clinical aspects of Buerger's disease in Japan. [2006.01]
Changes in plasma protein extravasation in rat skin during inflammatory challenges evaluated by microdialysis. [2006.05]
Closed transventricular aortic valvotomy for critical aortic stenosis in neonates: outcomes, risk factors, and reoperations. [2006.01]
[The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice] [2005.10]
Effect of prostaglandins against alloxan-induced diabetes mellitus. [2006.01]
Transdermal and topical pharmacotherapy for male sexual dysfunction. [2005.01]
|
